Open Access

Adrenal metastasis as first presentation of hepatocellular carcinoma

  • Kostas Tsalis1Email author,
  • Emmanouil Zacharakis1,
  • Nikolaos Sapidis1,
  • Ioannis Lambrou1,
  • Evangelos Zacharakis1 and
  • Dimitrios Betsis1
World Journal of Surgical Oncology20053:50

DOI: 10.1186/1477-7819-3-50

Received: 27 January 2005

Accepted: 25 July 2005

Published: 25 July 2005

Abstract

Background

Metastases from hepatocellular carcinoma (HCC) can be found in the lung and adrenal gland. We report case of a patient who presented with adrenal metastasis as the first clinical manifestation of HCC.

Case presentation

A patient was referred for surgical treatment for a tumor in retro-peritoneal space. The computerized tomography (CT) scan revealed a mass originating from the left adrenal gland. The patient underwent left adrenalectomy and the exploration of abdominal cavity did not reveal any other palpable lesions. Histologically, the resected lesion was a poorly differentiated metastatic tumor from HCC. Seven months later patient was readmitted complaining of cachexia, icterus, and significant weight loss. CT scan revealed hyperdense lesions of the liver

Conclusion

HCC may have atypical presentations like in present case. Fine needle aspiration/tru-cut® biopsy might be useful in the investigation of an accidentally discovered adrenal mass regardless of the size and can lead to the detection of a primary tumor.

Background

Metastases from hepatocellular carcinoma (HCC) can be found in the lung and adrenal gland [1]. It has been reported that adrenal metastases from HCC are found in 8.4 % of autopsy cases, being the second most common site of metastasis after the lung [1]. Recent advances in diagnostic techniques and therapeutic methods have contributed to an improved prognosis for patients with HCC [2].

Despite the fact that adrenal metastases from HCC are well documented, it is rare to have adrenal metastasis as the first clinical manifestation.

Case presentation

A 76 year old man was refferd from a District Hospital for further treatment of a tumor in retro-peritoneal space, originating from the left adrenal gland.

The patient was admitted to the District Hospital for investigation of macroscopic haematuria and lumbar pain during the last 48 hours. He had a past medical history of hypertension and hepatitis B. The laboratory investigations revealed hypercalcaemia and in an abdominal ultrasound scan (US), a mass was detected in the retroperitoneal space close to the left kidney. Then a Computed Tomography (CT) scan with contrast was performed which revealed an enhancing mass, 10 cm in diameter, between the pancreas and the left kidney originating from the left adrenal gland. No other pathological findings from intra or extra-peritoneal organs were identified (Figure 1). The serum alpha-fetoprotein (AFP) concentration was 75.6 ng/ml (normal range: 0–10 ng/ml) and C19-9 concentration 37.6 ng/ml, while the liver function tests were normal.
Figure 1

CT scan showing left adrenal gland tumor 10 cm in diameter, having homogenous intensity. No liver lesion is visualized.

After his admission to our Department, the patient was tested for underlying hormonally active tumor by low dose (1 mg) overnight dexamethasone suppression test and a 24-hour urine collection for catecholamines, cortisol, 17-ketosteroids, metanephrines and vanillylmandelic acid. As the patient was hypertensive, plasma aldosterone and plasma rennin were also tested. None of the tests indicated a functional adrenal tumor. The patient was under surveillance due to hepatitis B and had been subjected to AFP measurement and US scan 2, 8 and 14 months prior to his admission (AFP: 65, 69 and 60 ng/ml respectively). Regarding the facts that there was not remarkable increase in the AFP level during the last 14 months, the multiple US scans were negative and the CT scan on admission did not reveal any intrahepatic lesion, HCC was not considered in our patient.

With a presumptive diagnosis of a non-functional adrenal tumor, the patient underwent left adrenalectomy through a left Köcher incision. The exploration of the other intra-peritoneal organs did not reveal any other palpable lesions while the liver was found to be cirrhotic during the operation. The resected lesion was a firm elastic mass measuring 11.5 cm by 7.5 cm (Figure 2). The postoperative course was uneventful and the patient was discharged on day 7. Histologically, the resected lesion was a poorly differentiated metastatic HCC with trabecullar patterns. The patient was then informed of the findings and contacted for readmission, further investigation and adjuvant therapy. However, despite our repeated attempts, the patient refused to be subjected to any further investigation or treatment.
Figure 2

The resected adrenal mass was 11.5 cm by 7.5 cm in size.

Seven months later patient presented with cachexia, icterus, abdominal discomfort and significant weight loss (more than 10 % of body weight). The serum alpha-fetoprotein (AFP) concentration was 1620.5 ng/ml and the serum bilirubin 5.4 mg/dL. CT scan revealed hyperdense lesions of the liver (Figure 3). Even though Trans-Arterial Embolization (TAE) was then performed, the serum AFP concentration showed persistently elevation to 3543 ng/ml one month later, and the patient died 3 months after readmission due to rapidly progressive liver failure.
Figure 3

Hyperdense lesions of the liver in the arterial phase of the CT scan.

Discussion

Adrenal gland is the second most common site of hematogenous spread from HCC after the lung and has been found in up to 8.4% of cases at autopsy [1]. It is not clear why the adrenal gland has a greater incidence of metastases from HCC than other organs, however, it is claimed that the most likely route of metastases is the arterial spread via the aorta [3].

Adrenal metastasis in HCC are seldom treated by surgery as by the time they are diagnosed, the tumor is usually far advanced and the patients present with locally advanced primary hepatic lesions and poor liver function [4]. In our case, the adrenal metastasis was the first clinical presentation of HCC and till that time the primary tumor was not apparent on CT or US scan thus making it possible for us to resect the adrenal tumor.

At present, there is a wide variation in therapeutic modalities for adrenal metastases from HCC, as the tumor is usually accompanied by other distant or intrahepatic metastases and the patients are not always fit for a major operation. Trans-arterial embolization has been used for non-surgical treatment of these tumors. Sakamoto et al [5] stated that a complete TAE is difficult because the adrenal gland has three feeding arteries. Taniai et al [6] reported that despite the fact that adrenalectomy is the most effective way to control adrenal metastases from HCC, TAE is chosen as treatment of choice when the patients' performance status is too poor to tolerate an operation. Finally, ultrasound-guided percutaneous ethanol injection therapy (PEIT) is claimed to have technical difficulties and carry the additional risk of tumor seeding through the needle tract or bleeding from the punctured tumor [5, 7]. However, Momoi et al [8] in a retrospective study of 20 patients treated for adrenal metastasis of HCC by various methods reported that PEIT shows good results for small adrenal metastasis. In our case, adrenalectomy was our first option as the patient's condition allowed an operation and the diagnosis of a primary HCC had not been established by the CT scan imaging, the serum AFP concentration and the liver function tests during the preoperative period.

Recent advances in diagnostic imaging techniques such as CT scan or Magnetic Resonance Imaging (MRI) have significantly improved the ability of detection of liver lesions while there have not been any reports of metastatic lesions in the adrenal gland without clinical or CT scan finding of the primary HCC [6]. Recently, Iannaccone et al [9] reported that despite the use of updated equipment and optimized study protocols, CT scan has poor sensitivity for the detection of hepatocellular carcinoma. This is in contrast to Bartolozzi et al [10] who reported that Lipiodol-CT scan is the single most sensitive examination to detect small nodules of HCC, having a specificity of 86% compared to 62% for conventional CT scan. Similarly, Kitagawa et al [4] stated that MRI is more useful than CT scan for the assessment of primary liver tumors. In our case, patient preference not to be subjected to further investigation immediately after the histological diagnosis of metastatic HCC, prevented further imaging of the liver with either MRI and/or Lipiodol-CT scan, in order to identify and locate the primary lesion which may have been resectable at this stage. Moreover, our patient had an abdominal ultrasound scan which did not reveal any intrahepatic lesion. The combination of US and CT scan appears to have a sensitivity of 86% in detecting hepatocellular carcinoma [10]. We assume that the intrahepatic lesion might have been a small one at that stage making difficult its detection by conventional imaging.

The review of the literature revealed a few reports of metastases being the initial presentation of HCC. Ascani et al [11] reported a case of an osteolytic vertebral lesion to be the first manifestation, which was clinically silent until then. Similar reports with an initial finding of skeletal metastases from clinically silent HCC have been also presented by Omura et al [12] and Yang et al [13] who reported two cases. Besides, Baba et al [14] reported histological confirmation of HCC with right atrial metastasis to be the primary clinical manifestation. Finally, Gilsanz et al [15] reported a case of a patient who had a mass in the gluteal region for three years that turned out to be a metastasis of HCC. To our knowledge, this is the first case with adrenal metastasis as first presentation and subsequent histological confirmation of a silent HCC.

Incidentally discovered adrenal masses (incidentalomas) are fairly common, but the correct management of such lesions is not well established. Every patient with an incidentally discovered adrenal mass has to be investigated to detect malignancy and subtle hormonal overproduction in order to select the cases for surgical treatment. There are reports mentioning the value of fine needle aspiration/cut biopsy in differentiation of benign and malignant incidentalomas, stating that they are more sensitive than CT and MRI scan while size criteria are of little value [16]. Other authors recommend the use of FNA cytology in all patients with incidentalomas of more than 2 cm in size [17]. However, it is well documented that regardless of the endocrine status of an adrenal mass, the mass size especially if it is greater than 6 cm is a parameter associated with malignancy [18, 19]. Lesions greater than 6 cm in diameter have an approximate risk of 35% for malignancy [20]. Thus, many authors suggest that for prophylactic purposes, surgery should be considered in all patients with tumors greater than 6 cm [2123]. This was also our policy as the adrenal mass in our patient was non functional and its size was greater than 6 cm suggesting high-risk of malignancy. However, if fine needle aspiration/tru-cut® biopsy was performed, the primary tumor, which was obscure until then, might not have been missed until after the operation when the pathology report was available.

Conclusion

Atypical presentations of HCC are rare, adrenal metastasis can be the first clinical manifestation of the disease. Fine needle aspiration/needle biopsy might be useful in the investigation of an accidentally discovered adrenal mass regardless of the size as it can lead to the detection of a primary tumor, in case of metastatic disease, that is silent at this stage.

Declarations

Acknowledgements

Since the patient has died, consent could not obtained and his relatives have been lost from contact. The Scientific Council of 'G. Papanikolaou' General Regional Hospital decided to give its assent for the publication of data in medical journal.

Authors’ Affiliations

(1)
4th Surgical Department, Aristotle University of Thessaloniki, 'G. Papanikolaou' General Regional Hospital, Exohi

References

  1. Nakashima T, Okuda K, Kojiro M, Jojiro M, Jimi A, Yamagushi R: Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in ten years. Cancer. 1983, 51: 863-877.View ArticlePubMedGoogle Scholar
  2. Shuto T, Hirohashi K, Kudo S, Tanaka H, Tsukamoto T, Yamamoto T: Changes and results of surgical strategies for hepatocellular carcinoma: 452 consecutive patients over 15 years. Dig Surg. 1998, 28: 1124-1129.Google Scholar
  3. Yamashita N, Fykawa M, Imaizumi N, Matsumoto S, Tabuchi M, Hiroyoshi M: Establishing a diagnosis of adrenal metastasis from hepatocellular carcinoma by 99 m TC-PMT hepatobilliary scintigraphy. Jpn J Surg. 1992, 22: 565-567.Google Scholar
  4. Kitagawa Y, Tajika N, Kameoka N, Kanda Y, Watanabe T, Miura A: Adrenal metastasis from hepatocellular carcinoma – report of a case. Hepato-Gastroenterology. 1996, 43: 1383-1386.PubMedGoogle Scholar
  5. Sakamoto Y, Kubota K, Mori M, Inoue K, Abe H, Bandai Y: Surgical management for adrenal gland metastasis of hepatocellular carcinoma. Hepato-Gastroenterology. 1999, 46: 1036-1041.PubMedGoogle Scholar
  6. Taniai N, Egami K, Wada M, Tajiri T, Onda M: Adrenal metastasis from hepatocellular carcinoma (HCC): report of 3 cases. Hepato-Gastroenterology. 1999, 46: 2523-2528.PubMedGoogle Scholar
  7. Goletti O, De Negri F, Pucciarelli M, Sidoti F, Bertoluci A, Chiarugi M: Subcutaneous seeding after percutaneous ethanol injection of liver metastasis. Radiology. 1992, 183: 785-786.View ArticlePubMedGoogle Scholar
  8. Momoi H, Shimahara Y, Terajima H, Iimuro Y, Yamamoto N, Yamamoto Y: Management of adrenal metastasis from hepatocellular carcinoma. Surg Today. 2002, 32: 1035-1041. 10.1007/s005950200210.View ArticlePubMedGoogle Scholar
  9. Iannaccone R, Laghi A, Catalano C, Rossi P, Passariello R: Focal liver lesions in the cirrhotic patient: multislice spiral CT evaluation. Radiol Med. 2004, 107: 304-316.PubMedGoogle Scholar
  10. Bartolozzi C, Lencioni R, Caramella D, Palla A, Bassi AM, Di Candio G: Small hepatocellular carcinoma. Detection with US, CT, MR imaging, DSA, and Lipiodol-CT. Acta Radiol. 1996, 37: 69-74.PubMedGoogle Scholar
  11. Ascani S, Liberati F, Farabi R, Cristallini EG: Fine needle aspiration biopsy diagnosis of a bone metastasis from an occult carcinoma of the liver. A case report. Acta Cytol. 1995, 39: 547-549.PubMedGoogle Scholar
  12. Omura K, Kawaura Y, Murakami N, Morita K, Iwa T, Sasaki S: A hepatocellular carcinoma revealed by paraplegia caused by a vertebral metastasis. Gan No Rinsho. 1989, 35: 1448-1452.PubMedGoogle Scholar
  13. Yang WT, Yeo W, Leung SF, Chan YL, Johnson PJ, Metreweli C: MRI and CT of metastatic hepatocellular carcinoma causing spinal cord compression. Clin Radiol. 1997, 52: 755-760. 10.1016/S0009-9260(97)80154-7.View ArticlePubMedGoogle Scholar
  14. Baba HA, Engers R, Heintzen MP: Right atrial metastasis as primary clinical manifestation of hepatocellular carcinoma. Int J Cardiol. 1995, 47: 281-284. 10.1016/0167-5273(94)02193-M.View ArticlePubMedGoogle Scholar
  15. Gilsanz FC, Garcia CJ, Garcia RM, Rodriguez DR, Cabrero GF, Lopez RM: A gluteal mass as the initial manifestation of a calcified hepatocarcinoma. Rev Esp Enferm Apar Dig. 1989, 76: 181-184.Google Scholar
  16. Favia G, Lumachi F, Basso S, D'Amico DF: Management of incidentally discovered adrenal masses and risk of malignancy. Surgery. 2000, 128: 918-924. 10.1067/msy.2000.109965.View ArticlePubMedGoogle Scholar
  17. Lumachi F, Borsato S, Tregnaghi A, Basso SM, Marchesi P, Ciarleglio F, Fassina A, Favia G: CT-scan, MRI and image-guided FNA cytology of incidental adrenal masses. Eur J Surg Oncol. 2003, 29: 689-692. 10.1016/S0748-7983(03)00159-8.View ArticlePubMedGoogle Scholar
  18. Luton JP, Martinez M, Coste J, Bertherat J: Outcome in patients with adrenal incidentalomas selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur J Endocrinol. 2000, 143: 111-117. 10.1530/eje.0.1430111.View ArticlePubMedGoogle Scholar
  19. Bulow B, Ahren B: Adrenal incidentalomas-experience of a standardized diagnostic programme in the Swedish prospective study. J Intern Med. 2002, 252: 239-246. 10.1046/j.1365-2796.2002.01028.x.View ArticlePubMedGoogle Scholar
  20. Copeland PM: The incidentally discovered adrenal mass. Ann Intern Med. 1983, 98: 940-945.View ArticlePubMedGoogle Scholar
  21. Kasperlick-Zeluska AA, Roslonowska E, Slowinska-Srzednicka J, Migdalska B, Jeske W, Makowska A, Snochowska H: Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf). 1997, 46: 29-37. 10.1046/j.1365-2265.1997.d01-1751.x.View ArticleGoogle Scholar
  22. Chapuis Y, Dousset B, Bonnichon P, Massault PP, Hoeffel C, Louvel A: Which adrenal incidentalomas are to be operated?. Ann Chir. 2001, 126: 985-991. 10.1016/S0003-3944(01)00650-2.View ArticlePubMedGoogle Scholar
  23. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (incidentaloma). NIH Consensus Statement Sci Statements. 2002, 19: 1-25.

Copyright

© Tsalis et al; licensee BioMed Central Ltd. 2005

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement